retatrutide clinical trial phase retatrutide Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments ESC 2024: Retatrutide improves lipid

is supported by the American Heart AssociationBristol Myers Squibb Foundation through the Winn Diversity in Clinical Trials Clinical Investigator Leadership Award, and by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Physician-Scientist Career Development Award, Grant Number K12DK133995 (David Maahs, Linda DiMeglio, Multi-Center Program Directors)

The decision concerning choice of medication should be made in consultation with healthcare specialists, such as those at Set Point, who can provide a comprehensive medical weight loss management plan tailored to the patient

GLP-1 medications interact with numerous drugs, supplements, and substancessome reducing efficacy, others amplifying side effects

-Additionally, topline data from the Phase 2 exploratory basket MC4R variant study are expected in Fall 2022.

Lillys Phase 2 data showed that starting at 2 mg rather than 4 mg reduced nausea and vomiting during the stepping-up phase

GLP-1 Therapy vs